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Formal Infectious Diseases Specialist Consultation 
Improves Long-term Outcome of Methicillin-Sensitive 
Staphylococcus aureus Bacteremia
Erik Forsblom,* Hanna Frilander,* Eeva Ruotsalainen, and Asko Järvinen
Division of Infectious Diseases, Inflammation Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
Background. Formal infectious diseases specialist (IDS) consultation has been shown to improve short-term outcomes in 
Staphylococcus aureus bacteremia (SAB), but its effect on long-term outcomes lacks evaluation.
Methods. This retrospective study followed 367 methicillin-sensitive (MS) SAB patients for 10 years. The impact of formal IDS 
consultation on risk for new bacteremia and outcome during long-term follow-up was evaluated. Patients who died within 90 days 
were excluded to avoid interference from early deceased patients.
Results. Three hundred four (83%) patients had formal IDS consultation, whereas 63 (17%) received informal or no IDS consul-
tation. Formal consultation, compared with informal or lack of consultation, was associated with a reduced risk of new bacteremia 
caused by any pathogen within 1 year (odds ratio [OR], 0.39; 95% confidence interval [CI], 0.18–0.84; P = .014; 8% vs 17%) and 
within 3 years (OR, 0.39; 95% CI, 0.19–0.80; P = .010; 9% vs 21%), whereas a trend toward lower risk was observed within 10 years 
(OR, 0.56; 95% CI, 0.29–1.08; P = .079; 16% vs 25%). Formal consultation, compared with informal or lack of consultation, improved 
outcomes at 1 year (OR, 0.16; 95% CI, 0.06–0.44; P < .001; 3% vs 14%), at 3 years (OR, 0.19; 95% CI, 0.09–0.42; P < .001; 5% vs 22%), 
and at 10 years (OR, 0.43; 95% CI, 0.24–0.74; P = .002; 27% vs 46%). Considering all prognostic parameters, formal consultation 
improved outcomes (HR, 0.42; 95% CI, 0.27–0.65; P < .001) and lowered risk for any new bacteremia (OR, 0.45; 95% CI, 0.23–0.88; 
P = .02) during 10 years of follow-up.
Conclusions. MS-SAB management by formal IDS consultation, compared with informal or lack of IDS consultation, reduces 
risk for new bacteremia episodes and improves long-term prognosis up to 10 years.
Keywords. infectious diseases specialist consultation; long-term outcome; Staphylococcus aureus bacteremia.
Staphylococcus aureus causes severe bacteremia (SAB), with 
mortality ranging up to 30% [1]. Infectious diseases specialist 
(IDS) consultations improve clinical management of SAB. 
IDS consultation has been shown to accelerate diagnostics 
and eradication of infection foci [2–4] and improve choice 
and duration of antimicrobial therapy [5]. The superiority of 
formal IDS consultation, compared with informal IDS con-
sultation, has been demonstrated [6]. Above all, IDS con-
sultation improves SAB prognosis, and IDS is advocated as 
a mandatory practice in SAB management by an increasing 
number of clinicians [2–8].
Most studies on long-term outcome in SAB have evaluated 
prognostic factors up to 1 year [9–14], whereas few analyses 
are available on 2–5  years [15–17] or 10  years of follow-up 
[18–20]. Parameters linked to shorter survival in these studies 
have been: older age [9–13, 15–18], underlying conditions 
[12–17], severe sepsis or septic shock [12, 20], unknown infec-
tion focus [10, 14, 18, 20], pneumonia [10, 20] and methicillin-
resistant S.  aureus (MRSA) [11], whereas adequate empiric 
antibiotic therapy has been connected to improved survival [3, 
14]. However, the role of IDS consultation on long-term out-
comes in SAB has received surprisingly little attention. Most 
reports on long-term follow-up of SAB have not included or 
commented on the role of IDS consultation [10–15, 17, 20]. 
Five studies provided IDS consultation or an infectious dis-
eases team to 12%–90% of patients, concluding an improved 
1-year outcome [3, 18] or improved clinical management [21, 
22] whereas 1 report did not specify what clinical or prog-
nostic impact IDS provided [20]. Two of the reports specified 
IDS consultation as formal or routine [3, 22]. There are no re-
ports on the effect of IDS consultation on long-term outcome 
beyond 1 year after SAB.
The objective here was to investigate the impact of formal IDS 
consultation, compared with informal or no IDS consultation, 
applyparastyle “fig//caption/p[1]” parastyle “FigCapt”
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on risk for new bacteremia and outcome during 10  years of 
follow-up after methicillin-sensitive (MS) SAB. Exclusion of 
patients who died within 90 days enabled evaluation of param-
eters affecting only long-term outcome. Inclusion of MS-SAB 
enabled a setting in which each patient received proper 
nondelayed antibiotics from the first day of SAB, thus avoiding 
the impact of differences in empirical antibiotic choice.
METHODS
Study Population
The present study included all adult patients with at least 1 
positive blood culture for methicillin-sensitive S. aureus from 
Helsinki University Central Hospital in Finland identified 
during January 1999 to May 1999, January 2000 to August 2002, 
and 2006 to 2007. Clinical patient data were retrieved from 
both written (1999–2002) and electronic (2006–2007) patient 
records. Bacteremia due to MRSA were omitted (altogether 5 
cases in 1999–2002 and no cases in 2006–2007). We followed 
patient records meticulously for 90 days. Data documentation 
included gender, age, comorbid diseases, infection acquisition, 
illness severity, antibiotic therapy, radiological and laboratory 
findings, infection foci, IDS consultation, hospitalization, and 
outcome. Infection foci were verified by radiological, bacteri-
ological, or pathological investigations or by clinical suspicion. 
Follow-up continued from hospital records for 10  years after 
the initial 90 days. Data on date and causative pathogen of any 
new bacteremia and date of death were recorded. Dead or alive 
status was retrieved from the Population Register Centre, which 
includes data on all people in Finland.
Definitions
McCabe’s criteria were applied for classification of underlying 
conditions and comorbid diseases [23]. Patients with McCabe’s 
healthy and nonfatal classification were viewed as lacking se-
vere underlying diseases.
SAB was defined as nosocomial (health care associated) 
when the first positive blood culture for S. aureus was received 
(i) ≥48 hours after admission to a hospital or (ii) within ≤48 
hours of hospital admission with a preceding previous hospital 
discharge within 7 days. Severe sepsis was categorized as sepsis 
in combination with hypotension, hypoperfusion, or organ 
failure [24]. The modified Duke criteria were applied for defi-
nition of endocarditis [25]. The Pitt bacteremia score was used 
for severity of illness evaluation [26]. IDS consultation within 
7 days of SAB was categorized as (i) formal IDS, (ii) informal 
IDS, or (iii) no IDS consultation. Formal consultation was a 
bedside consultation by the IDS including physical examina-
tion, review of patient records, and written directives on clinical 
management. Informal consultation was recorded when direct-
ives given by the IDS on management were given by telephone 
(or any informal communication) and the treating physician 
documented the directives in the records. Lack of IDS consulta-
tion was defined as no consultation [6].
Outcome
The primary outcome was mortality rate and occurrence of any 
new bacteremia during 1, 3, and 10 years.
Statistical Analyses
Categorical variables were compared with Pearson’s chi-square 
test, and noncategorical variables with the Student t test. Odds 
ratios (ORs) and hazard ratios (HRs) with 95% confidence 
intervals (CIs) were calculated. Univariate factors with P <  .1 
were allowed into the Cox regression model (proportional haz-
ards regression) (Table 4) for estimation of prognostic param-
eters and into multivariate analysis (Table 5) for estimation of 
parameters predicting risk for new bacteremia. The Kaplan-
Meier method was applied for survival estimates. Patients who 
died within 90 days were excluded from all analyses to enable 
statistical calculations of long-term prognostic parameters 
without interference from early deceased patients. Tests were 
2-tailed, and P < .05 was considered significant. Analyses were 
done with SPSS 12.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
Patient Characteristics
We identified a total of 440 patients with MS-SAB; however, 
73 (17%) patients died during the initial 90 days and were ex-
cluded. Formal IDS consultation was received by 304 (83%), 
whereas 63 (17%) were managed through informal IDS con-
sultation or without consultation. No differences regarding 
age, gender, or bacteremia acquisition were observed between 
the 2 groups (Table 1). Patients with formal IDS consultation, 
compared with patients with informal or lack of IDS consul-
tation, had less hematological malignancy and more injection 
drug use (IDU), and no other differences were seen regarding 
other underlying conditions. When comparing patients with 
formal IDS consultation with patients with informal or lack of 
IDS consultation, no differences were seen regarding McCabe’s 
healthy, nonfatal, ultimately fatal, or rapidly fatal classification 
of diseases (Table 1). No differences on severe sepsis, intensive 
care unit, or Pitt bacteremia scores were seen between patients 
with formal IDS consultation and those with informal or no 
IDS consultation (Table 1).
Clinical Management
Altogether, 260 (71%) patients had a deep infection focus. 
Formal IDS consultation, compared with informal or no IDS 
consultation, was associated with more radiological exam-
inations, transesophageal echocardiography, computed to-
mography scans, and leukocyte indium-111 scintigraphy and 
more deep infection foci. Furthermore, deep infection focus 
eradication was received by 27% of patients with formal IDS 
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consultation whereas 11% of patients with formal IDS consul-
tation had infected foreign bodies removed. Contrary to this, 
patients managed by informal IDS or without any IDS did not 
undergo any infection eradications (Table 2).
Antibiotic Therapy
From the first day of positive blood culture, each patient was 
treated with an intravenous antimicrobial agent effective in 
vitro against the S. aureus blood isolate. Most patients received 
an antistaphylococcal penicillin 76%, whereas 17% had cepha-
losporin and 7% vancomycin, clindamycin, or a carbapenem. 
Adjunctive fluoroquinolone, rifampicin, or aminoglycoside 
was received by 51%, 54%, and 16% of patients, respectively. 
Patients with formal IDS consultation, compared with patients 
managed by informal IDS consultation or without IDS consul-
tation, had more antistaphylococcal penicillin, more adjunctive 
rifampicin, and less cephalosporin, vancomycin, clindamycin, 
or carbapenem therapy, whereas no difference was seen with re-
spect to adjunctive fluoroquinolone or aminoglycoside therapy 
(Table 2).
Outcome
The 1-, 3-, and 10-year overall mortality rates after exclusion 
of patients who died within the first 90  days were 5%, 8%, 
and 30%, respectively. Mortality among patients who received 
formal IDS consultation, as compared with patients with in-
formal or no IDS consultation, was lower at 1 year, at 3 years, 
and at 10 years (Table 3). In Cox proportional regression model 
analysis, prognostic factors at 1, 3, and 10 years were very sim-
ilar. At the 2 later time points, the only parameter for poor out-
come was age  >65  years, whereas lack of underlying diseases 
and formal IDS consultation were connected to better outcome 
at all 3 time points (Table 4, Figure 1). The Cox proportional 
regression analyses were re-performed by excluding patients 
Table 1. Demographics, Underlying Conditions, and Illness Severity of 367 Methicillin-Sensitive Staphylococcus aureus Bacteremia Patients who 
Survived the First 90 Days; Categorization According to Formal Infectious Specialist Consultation
Parameters
Formal Infectious Diseases Specialist Consultation
Present n = 304 (83) Absent n = 63 (17) ORs (95% CI) P
Demographics     
 Male gender 205 (67) 38 (60) 1.36 (0.78–2.38) .28
 Age >65 y 96 (32) 15 (24) 1.48 (0.79–2.77) .22
 Age, mean ± SD, y 54.5 ± 18 52.4 ± 16 — .24
 Nosocomial bacteremia 143 (47) 38 (60) 0.58 (0.34–1.02) .06
Underlying conditions     
 McCabe’s classificationa     
 Healthy 30 (10) 5 (8) 1.27 (0.47–3.41) .64
 Nonfatal 210 (69) 37 (58) 1.57 (0.89–2.74) .11
 Ultimately fatal 62 (20) 19 (30) 0.59 (0.32–1.09) .089
 Rapidly fatal 2 (1) 2 (3) 0.20 (0.03–1.46) .080
 Coronary artery disease 56 (18) 14 (22) 0.79 (0.41–1.53) .49
 Pulmonary disease – acute or chronic 45 (15) 8 (13) 1.19 (0.53–2.68) .67
 Liver disease – acute or chronic 56 (18) 7 (11) 1.81 (0.78–4.17) .16
 Diabetes mellitus 36 (12) 10 (16) 0.71 (0.33–1.52) .38
 Chronic renal failureb 34 (11) 9 (14) 0.76 (0.34–1.67) .49
 Malignancy     
  Nonhematological 23 (8) 8 (13) 0.56 (0.24–1.32) .18
  Hematological 6 (2) 16 (25) 0.06 (0.02–0.16) .001
 IDUc 51 (17) 3 (5) 4.03 (1.22–13.3) .014
 HIV 10 (3) 0 — —
Severity of illness     
 Severe sepsisd 19 (6) 6 (10) 0.63 (0.24–1.66) .35
 ICU treatment, within 24 h 55 (18) 13 (21) 0.85 (0.43–1.67) .64
 ICU treatment, with 7 d 77 (25) 17 (27) 0.92 (0.49–1.69) .78
 Pitt score ≥3d,e 23 (8) 6 (10) 0.75 (0.29–1.92) .54
 Pitt score, mean ± SDd,e 0.59 ± 1.4 0.65 ± 1.6 — .29
Data are No. (%) of patients. Hazard ratios and 95% confidence intervals are presented. 
Abbreviations: CI, confidence interval; ICU, intensive care unit; ORs, odds ratio. 
aUnderlying diseases characterized according to McCabe and Jackson [23]. 
bChronically elevated serum creatinine (≥180 mmol/L). 
cInjection drug use within preceding 6 months. 
dAt blood culture collection. 
ePitt bacteremia scores [26].
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with hematological malignancy. The results were very similar 
to those in Table 4, with formal IDS consultation connecting to 
a positive prognosis at 1-, 3-, and 10-year follow-up. To further 
evaluate the long-term prognostic impact of formal IDS consul-
tation, we re-performed the analyses by excluding patients who 
died within the first 3 years (n = 30). When the prognostic im-
pact of formal IDS consultation on survival during 3–10 years 
was evaluated, the following results were achieved: OR, 0.66; 
95% CI, 0.34–1.29; P = .22.
The risk for a new bacteremia episode caused by any 
pathogen was 9% (34), 11% (41), and 18% (65), and the 
risk for a new episode of SAB was 4% (14), 4% (15), and 6% 
(22) at 1-, 3-, and 10-year follow-up, respectively (Table 3). 
During the 10 years of follow-up, the 3 most common bac-
teremia pathogens were (1) 22 cases of Staphylococcus au-
reus; (2) 8 cases of various Streptococci including 3 cases of 
Streptococcus viridans; 3 cases of Streptococcus pneumoniae 
and 2 cases of Streptococcus pyogenes; and (3) 7 cases of 
Escherichia coli.
Formal IDS consultation, compared with informal or no IDS 
consultation, was connected to a lower risk for new bacteremia 
episodes at 1 year, at 3 years, and at 10 years (Table 3). However, 
within 10 years of follow-up, formal IDS consultation, compared 
with informal or no IDS consultation, presented no reduced 
risk for a new episode of SAB. In multivariate analysis, factors 
reducing the risk for any new bacteremia episode within 1 and 
3 years were lack of underlying diseases and formal IDS consulta-
tion, whereas IDU increased the risk. At 10-year follow-up, IDU 
increased and formal IDS consultation decreased the risk for 
any new bacteremia episode (Table 5). The multivariate analyses 
were re-performed by excluding patients with hematological 
malignancies. The results were very similar to those in Table 5: 
Formal IDS consultation reduced the risk for any new bacte-
remia episode at 1 year, 3 years, and 10 years of follow-up.
Table 2. Radiology, Infections, and Antimicrobial Therapy in 367 Methicillin-Sensitive Staphylococcus aureus Bacteremia Patients who Survived the 
First 90 Days; Categorization According to Formal Infectious Diseases Specialist Consultation
Parameters
Formal Infectious Diseases Specialist Consultation
Present n = 304 (83) Absent n = 63 (17) ORs (95% CI) P
Radiological investigations     
 Echocardiography     
  Transthoracic 204 (67) 38 (60) 1.34 (0.77–2.35) .30
  Transesophageal 44 (14) 1 (2) 10.5 (1.42–77.6) .005
 Whole-body computed tomography     
   ≥1 per patient 203 (67) 31 (49) 2.08 (1.12–3.59) .008
   No. per patient, mean ± SD 1.10 ± 1.0 0.49 ± 0.5 — .004
 Magnetic resonance imaging     
   ≥1 per patient 64 (21) 0 — —
 No. per patient, mean ± SD 0.29 ± 0.6 0 — —
 Leukocyte indium-111 scintigraphy 127 (42) 7 (11) 5.74 (2.53–13.0) <.001
Infection focus and eradication     
 Pneumonia 112 (37) 11 (17) 2.76 (1.38–5.50) .003
 Endocarditis 40 (13) 2 (3) 4.62 (1.09–19.6) .023
 Osteomyelitis and/or septic arthritis 120 (39) 6 (10) 6.23 (2.60–14.9) <.001
 Any deep infection focus 236 (78) 24 (38) 5.64 (3.17–10.0) <.001
 Eradication of deep infection focusa 83 (27) 0 — —
 Eradication of infected foreign body 34 (11) 0 — —
Antimicrobial therapy     
 Antistaphylococcal penicillinb 255 (84) 25 (40) 7.91 (4.38–14.3) <.001
 Cephalosporinec 40 (13) 23 (37) 0.26 (0.14–0.49) <.001
 Other therapyd 9 (3) 15 (24) 0.09 (0.04–0.24) <.001
   Vancomycin 7 (2) 3 (5) 0.47 (0.12–1.88) .28
 Fluoroquinolonee 159 (52) 27 (43) 1.46 (0.85–2.53) .17
 Aminoglycosidee 47 (15) 13 (21) 0.70 (0.36–1.39) .31
 Rifampicine,f 174 (57) 23 (37) 2.33 (1.33–4.08) .003
Data are No. (%) of patients. Hazard ratios and 95% confidence intervals are presented. 
Abbreviations: CI, confidence interval; ORs, odds ratio.
aSurgical or radiological eradication. 
bCloxacillin. 
cCefuroxime or ceftriaxone. 
dVancomycin, clindamycin, or a carbapenem.
eAdjunctive antimicrobial therapy. 
fTherapy duration ≥14 days.
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DISCUSSION
The main observations were that formal IDS consultation, 
compared with informal or no IDS consultation, improved 
long-term outcomes in MS-SAB patients. Accounting for all 
prognostic parameters, MS-SAB patients had a 4–5-fold lower 
risk for a fatal outcome during 1 and 3 years of follow-up and 
an almost 2-fold lower risk for a fatal outcome during 10 years 
of follow-up due to formal IDS consultation. A  similar trend 
was seen for risk of any new bacteremia during long-term fol-
low-up: MS-SAB patients had a 3-fold lower risk during 1 and 
3 years of follow-up and an almost 2-fold reduced risk during 
10 years of follow-up due to formal IDS consultation.
The importance of deep infection localization and eradica-
tion and the potential connection of undiagnosed infection 
focus with mortality have been demonstrated repeatedly in SAB 
[27–30]. Identification of deep infection focus has been shown 
to improve 1- and 5-year prognosis after SAB [10, 14, 18, 20]. 
Previous reports on long-term outcome in SAB have provided 
echocardiography to 44%–64% of patients [3, 10, 21, 22] and 
identified deep infection focus in 11%–38% [3, 9, 10, 14, 22] with 
endocarditis in 4%–27% [3, 10, 14, 18, 21, 22] and osteomye-
litis and/or septic arthritis in 10%–27% of patients [3, 9, 22]. The 
present study demonstrated a strong connection of formal IDS 
consultation with radiological investigations, resulting in deep 
infection focus identification in up to 78%. However, in patients 
managed through informal IDS consultation or without IDS 
consultation, deep infection focus was identified in 43% of cases 
only, and no infection focus eradication was provided.
The impact of IDS consultation–guided clinical management 
on long-term outcome in SAB has received little attention. Two 
prospective studies have provided IDS consultation for all SAB 
patients: 1 report had all patient cases reviewed by 2 infectious 
diseases specialists [9], and a second report investigated bacte-
remia of various pathogens (42% SAB) and provided bedside 
infectious diseases physician evaluation to all cases [16]. A third 
report had 12% of patients supervised by an infectious diseases 
team and concluded that lack of supervision was connected to 
poorer long-term outcome [18]. Another 3 reports provided 
IDS consultation to 27% [3], 74% [21], and 90% [22] of SAB 
patients and concluded that IDS consultation improved the 
1-year outcome [3] or increased compliance [21, 22]. Contrary 
to the studies mentioned above, 1 report providing IDS consul-
tation to 25% of SAB patients presented no benefit as a result 
of the consultation [20]. However, the explicit content and im-
pact of the IDS consultation were not described [9, 16, 18, 20, 
21]. Detailed content and impact of the IDS consultation have 
been specified in only 2 previous studies, which concluded that 
formal IDS consultation [3] or routine IDS consultation [22] 
enhanced choice and duration of antimicrobial therapy and in-
creased diagnostics of deep infection focus and endocarditis [3, 
22]. However, only 1 of these 2 reports connected formal IDS 
consultation to improved 1-year outcome [3]. We have previ-
ously shown that informal IDS consultation cannot achieve the 
benefits in short-term survival that have been seen with formal 
bedside IDS [6]. Hence, despite solid evidence that IDS con-
sultation improves short-term outcome in SAB patients, no re-
ports are available on the detailed content and impact of IDS 
consultation on a 1–10-year long-term outcome.
The present study excluded patients who died within 90 days 
to enable statistical analyses without interference from early de-
ceased patients. This enabled evaluation of prognostic param-
eters that influence outcome after the initial 90 days. Moreover, 
to further evaluate the long-term prognostic impact of formal 
IDS consultation, we re-performed the analyses by excluding 
Table 3. Risk for New Bacteremia and Outcome in 367 Methicillin-Sensitive Staphylococcus aureus Bacteremia Patients who Survived the First 90 Days; 
Categorization According to Formal Infectious Diseases Specialist Consultation
Parameters
Formal Infectious Diseases Specialist Consultation
Present n = 304 (83) Absent n = 63 (17) ORs (95% CI) P
Risk for new bacteremia     
 Within 1 y     
  New bacteremia due to any pathogen 23 (8) 11 (17) 0.39 (0.18–0.84) .014
  SAB relapse 9 (3) 5 (8) 0.77 (0.18–3.29) .73
 Within 3 y     
  New bacteremia due to any pathogen 28 (9) 13 (21) 0.39 (0.19–0.80) .010
  SAB relapse 10 (3) 5 (8) 0.89 (0.23–3.46) .87
 Within 10 y     
  New bacteremia due to any pathogen 49 (16) 16 (25) 0.56 (0.29–1.08) .079
  SAB relapse 17 (6) 5 (8) 0.69 (0.24–1.94) .47
Mortality, within     
 1 y 8 (3) 9 (14) 0.16 (0.06–0.44) <.001
 3 y 16 (5) 14 (22) 0.19 (0.09–0.42) <.001
 10 y 81 (27) 29 (46) 0.43 (0.24–0.74) .002
Data are No. (%). Hazard ratios and 95% confidence intervals are presented. 
Abbreviations: CI, confidence interval; ORs, odds ratio; SAB, Staphylococcus aureus bacteremia.
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patients who died within the first 3  years and investigated 
parameters affecting survival during 3–10  years. However, 
when excluding patients who died within the first 3 years, no 
prognostic impact of formal IDS consultation on 3–10-year 
survival was observed. Hence, it appears that the major positive 
prognostic impact of formal IDS consultation is seen within the 
first 3 years, and for patients who survive past the first 3 years, 
the outcome during the following years is irrespective of formal 
IDS consultation. To the best of our knowledge, only 3 studies 
have excluded early deceased patients, that is, patients who died 
within 3–30 days [3, 9, 14]. Previous reports on SAB outcome, 
including studies that excluded early deceased patients, have 
presented mortality rates of 32%–47% at 1 year, 48% at 3 years, 
and 76% at 10 years [9, 10, 14, 16, 18, 19]. The mortality rates 
of the present study are far lower than in these previous reports. 
However, comparison of mortality figures requires caution, as 
the present study excluded patients who died early.
The present study connected age and underlying condi-
tions to poorer long-term prognosis at 1, 3, and 10 years of fol-
low-up, which is in line with previous reports [9, 10, 11, 14, 15]. 
Long-term prognosis in the present report was not affected by 
severe sepsis, pneumonia, or endocarditis, that is, parameters 
frequently associated with poorer short-term (30–90  days) 
outcome [2–6]. These observations are in line with 1 previous 
report that excluded patients who died within 30 days and sup-
port the idea that short-term mortality is mainly influenced by 
Table 4. Cox Proportional Regression Model Analysis for Prognostic Factors for 1-, 3-, and 10-Year Mortality in 367 Methicillin-Sensitive Staphylococcus 
aureus Bacteremia Patients who Survived the First 90 Days
Univariate Analysis Multivariate Analysis
1-y Mortality Died n = 17 (5) Survived n = 350 (95) ORs (95% CI) P HRs (95% CI) P
Male gender 13 (76) 230 (66) 1.69 (0.54–5.31) .36 — —
Age >65 y 9 (53) 102 (29) 2.74 (1.03–7.29) .037 — —
Healthy nonfatal diseasea 6 (35) 276 (79) 0.15 (0.05–0.42) <.001 0.18 (0.07–0.50) .001
Nosocomial bacteremia 12 (71) 169 (48) 2.57 (0.89–7.45) .072 — —
Severe sepsisb 2 (12) 23 (7) 1.89 (0.41–8.79) .41 — —
Pneumonia 6 (35) 117 (33) 1.09 (0.39–3.01) .87 — —
Endocarditis 0 42 (12) — — — —
Bedside IDS consultation 8 (47) 296 (85) 0.16 (0.06–0.44) <.001 0.21 (0.08–0.55) .001
Telephone or no IDS consultation 9 (53) 54 (15) 6.17 (2.28–16.7) <.001 — —
Rifampicinc 11 (65) 186 (53) 1.62 (0.59–4.47) .35 — —
3-y mortality Died n = 30 (8) Survived n = 337 (92) ORs (95% CI) P HRs (95% CI) P
Male gender 22 (73) 221 (66) 1.44 (0.62–3.34) .39 — —
Age >65 y 15 (50) 96 (28) 2.51 (1.18–5.34) .014 2.15 (1.02–4.53) .045
Healthy nonfatal diseasea 11 (37) 271 (80) 0.14 (0.06–0.31) <.001 0.19 (0.09–0.42) <.001
Nosocomial bacteremia 19 (63) 162 (48) 1.87 (0.86–4.04) .11 — —
Severe sepsisb 3 (10) 22 (7) 1.59 (0.45–5.66) .47 — —
Pneumonia 11 (37) 112 (33) 1.16 (0.54–2.53) .70 — —
Endocarditis 1 (3) 41 (12) 0.25 (0.03–1.88) .15 — —
Bedside IDS consultation 16 (53) 288 (85) 0.19 (0.09–0.42) <.001 0.23 (0.09–0.44) <.001
Telephone or no IDS consultation 14 (47) 49 (15) 5.14 (2.36–11.2) <.001 — —
Rifampicinc 18 (60) 179 (53) 1.32 (0.62–2.83) .47 — —
10-y mortality Died n = 110 (30) Survived n = 257 (70) ORs (95% CI) P HRs (95% CI) P
Male gender 78 (71) 165 (64) 1.36 (0.84–2.21) .21 — —
Age >65 y 53 (48) 58 (23) 3.19 (1.98–5.13) <.001 2.37 (1.61–3.49) <.001
Healthy nonfatal diseasea 68 (62) 214 (83) 0.33 (0.19–0.54) <.001 0.46 (0.31–0.68) <.001
Nosocomial bacteremia 62 (56) 119 (46) 1.49 (0.96–2.35) .17 — —
Severe sepsisb 7 (6) 18 (7) 0.99 (0.37–2.22) .82 — —
Pneumonia 34 (31) 89 (35) 0.84 (0.52–1.36) .49 — —
Endocarditis 8 (7) 34 (13) 0.51 (0.23–1.15) .10 — —
Bedside IDS consultation 81 (74) 223 (87) 0.43 (0.24–0.74) .002 0.42 (0.27–0.65) <.001
Telephone or no IDS consultation 29 (26) 34 (13) 2.35 (1.35–4.09) .002 — —
Rifampicinc 58 (53) 139 (54) 0.95 (0.61–1.48) .81 — —
Data are No. (%) of patients. Hazard ratios and 95% confidence intervals are presented. 
Abbreviations: CI, confidence interval; HRs, hazard ratio; IDS, infectious diseases specialist; ORs, odds ratio. 
aUnderlying diseases characterized according to McCabe and Jackson [23]. 
bAt blood culture collection time point. 
cAdjunctive rifampicin therapy ≥14 days.
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severe infection-related complications such as severe sepsis or 
endocarditis, whereas long-term outcome is dictated by back-
ground parameters such as age and comorbidity [9]. Some pre-
vious reports have presented severe sepsis, septic shock, and 
pneumonia as drivers of long-term outcome in SAB [10, 12, 
20]. However, these studies have not excluded early deceased 
patients, and hence the degree to which these parameters im-
pact long-term outcomes is uncertain.
Relapse of SAB is common, and previous reports present re-
lapse rates of 5%–12% during 90 days of follow-up [5, 31–33]. 
Parameters recognized as independent risk factors for relapse 
are deep infection focus, endocarditis, unremoved infected cen-
tral venous line, and vancomycin therapy for MS-SAB [32–34]. 
Moreover, reports have connected IDS consultation to signif-
icantly reduced risk for SAB relapse during a short-term fol-
low-up period of 90 days [5, 31]. To the best of our knowledge, 
only 1 study has reported a 6% SAB relapse during 1-year fol-
low-up; in this study, each patient was provided IDS consulta-
tion [9]. We observed a rate of new SAB episodes of 4% at 1 
and 3 years of follow-up and 6% at 10 years of follow-up. In the 
Table 5. Multivariate Analysis for Factors Predicting the Risk for New Bacteremia due to any Pathogen During 1-, 3-, and 10-Year Follow-up in 367 
Methicillin-Sensitive Staphylococcus aureus Bacteremia Patients who Survived the First 90 Days
Univariate Analysis Multivariate Analysis
Bacteremia within 1 y Present n = 34 (9) Absent n = 333 (91) ORs (95% CI) P HRs (95% CI) P
Male gender 23 (68) 220 (66) 1.07 (0.51–2.28) .85 — —
Age >65 y 10 (29) 101 (30) 0.96 (0.44–2.08) .91 — —
Healthy nonfatal diseasea 19 (56) 263 (79) 0.34 (0.16–0.69) .002 0.18 (0.07–0.45) <.001
Nosocomial bacteremia 19 (56) 162 (49) 1.34 (0.66–2.72) .42 — —
IDUb 11 (32) 43 (13) 3.23 (1.47–7.08) .002 8.74 (3.20–23.8) <.001
Severe sepsisc 1 (3) 24 (7) 0.39 (0.05–2.98) .35 — —
Pneumonia 12 (35) 111 (33) 1.09 (0.52–2.29) .82 — —
Endocarditis 5 (15) 37 (11) 1.38 (0.50–3.78) .53 — —
Bedside IDS consultation 23 (69) 281 (84) 0.39 (0.18–0.84) .014 0.32 (0.14–0.75) .009
Telephone or no IDS consultation 11 (32) 52 (16) 2.58 (1.19–5.62) .014 — —
Rifampicind 17 (50) 180 (54) 0.85 (0.42–1.72) .65 — —
Bacteremia within 3 y Present n = 41 (11) Absent n = 326 (89) ORs (95% CI) P HRs (95% CI) P
Male gender 29 (66) 214 (66) 1.27 (0.62–2.57) .52 — —
Age >65 y  10 (24)  101 (31) 0.72 (0.40–1.52) .39 — —
Healthy nonfatal diseasea 24 (59) 258 (79) 0.37 (0.19–0.73) .003 0.17 (0.07–0.41) <.001
Nosocomial bacteremia 22 (54) 159 (49) 1.22 (0.63–2.33) .56 — —
IDUb 15 (37) 39 (12) 4.25 (2.07–8.71) <.001 12.1 (4.72–30.8) <.001
Severe sepsisc 2 (5) 23 (7) 0.68 (0.15–2.98) .60 — —
Pneumonia 14 (34) 109 (33) 1.03 (0.52–2.05) .93 — —
Endocarditis 7 (17) 35 (11) 1.71 (0.71–4.15) .23 — —
Bedside IDS consultation 28 (68) 276 (85) 0.39 (0.19–0.80) .009 0.29 (0.13–0.66) .003
Telephone or no IDS consultation 13 (32) 50 (15) 2.56 (1.24–5.28) .009 — —
Rifampicind 20 (49) 177 (54) 0.80 (0.42–1.54) .51 — —
Bacteremia within 10 y Present n = 65 (18) Absent n = 302 (82) ORs (95% CI) P HRs (95% CI) P
Male gender 44 (68) 199 (66) 1.08 (0.61–1.92) .78 — —
Age >65 y 17 (26) 94 (31) 0.78 (0.43–1.43) .43 — —
Healthy nonfatal diseasea 46 (71) 236 (78) 0.68 (0.37–1.23) .20 — —
Nosocomial bacteremia 34 (52) 147 (49) 1.16 (0.68–1.98) .59 — —
IDUb 19 (29) 35 (12) 3.15 (1.66–5.98) <.001 3.63 (1.87–7.02) <.001
Severe sepsisc 5 (8) 20 (7) 1.18 (0.42–3.26) .76 — —
Pneumonia 21 (32) 102 (34) 0.94 (0.53–1.66) .82 — —
Endocarditis 7 (11) 35 (12) 0.92 (0.39–2.18) .85 — —
Bedside IDS consultation 49 (75) 255 (84) 0.56 (0.30–1.08) .079 0.45 (0.23–0.88) .02
Telephone or no IDS consultation 16 (25) 47 (16) 1.77 (0.93–3.38) .079 — —
Rifampicind 31 (48) 166 (55) 0.75 (0.44–1.28) .29 — —
Data are No. (%) of patients. Hazard ratios and 95% confidence intervals are presented. 
Abbrevations: CI, confidence interval; HRs, hazard ratio; IDS, infectious diseases specialist consultation; ORs, odds ratio. 
aUnderlying diseases characterized according to McCabe and Jackson [23]. 
bInjection drug use within the preceding 6 months. 
cAt blood culture collection time point. 
dAdjunctive rifampicin therapy ≥14 days.
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present study, formal IDS consultation did not impact the risk of 
a new SAB episode during 1 to 10 years of follow-up. However, 
a significant reduction in risk for any new bacteremia episode 
due to formal IDS consultation during 1, 3, and 10 years of fol-
low-up was observed. The association of proper clinical man-
agement of SAB, due to formal IDS consultation, and reduced 
future risk for new bacteremia is difficult to explain. Previous 
studies have observed that patients who suffer from bacteremia, 
compared with matched control patients, are more morbid and 
have higher long-term mortality rates [15, 35]. This excess long-
term mortality is not completely understood, and it has been 
proposed that bacteremia might be a marker of comorbidity 
or an activator for a low-grade inflammatory response and 
infection-related inflammation resulting in the development of 
new diseases or accelerating earlier existing comorbidity, for ex-
ample, cardiovascular or renal disease [15, 36, 37].
There are weaknesses in the present study that have to be ac-
counted for when interpreting the results. First, the retrospec-
tive design includes risk for bias. Patients receiving formal IDS 
consultation, compared with patients with informal or no IDS 
consultation, had fewer hematological malignancies. However, 
analyses were performed twice, both including and excluding 
hematological malignancies, and the impact of formal IDS con-
sultation on long-term outcome and risk for new bacteremia 
episodes were almost identical. Second, the present study dem-
onstrated a connection between formal IDS consultation and 
reduced long-term mortality and risk for new bacteremia epi-
sodes, but this does not indicate a causal relationship. There is al-
ways the possibility that severely ill patients with presumed poor 
prognosis did not receive formal IDS consultation. However, 
the exclusion of patients who died during the first 90 days may 
have corrected this potential bias. Third, the patient cohort was 
originally gathered during January–May 1999, January 2000–
August 2002, and 2006–2007 for evaluation of the prognostic 
impact of fluoroquinolones, rifampicin, and IDS consultation in 
MS-SAB patients [6, 38, 39]. The fluoroquinolone trovafloxacin 
was initially included but was withdrawn from the market and 
later replaced by the fluoroquinolone levofloxacin. This explains 
why no patients were collected during June–December 1999. 
Considering the time periods of 1999–2002 and 2006–2007, 
it is plausible to discuss whether the data are valid for current 
medical practice. However, we wanted to include 2 separate time 
periods to exclude the possibility of temporary unidentified dif-
ferences in treatment practices or other factors that are difficult 
to control for. Furthermore, the possible disadvantage with ei-
ther information storage pattern was taken into account by in-
cluding both electronic and paper records.
In conclusion, the study indicates that formal IDS consulta-
tion, compared with informal or lack of consultation, improves 
long-term outcome and reduces risk for new bacteremia epi-
sodes. However, the relationship and implication of properly 
managed SAB and reduced risk of new bacteremia need further 
evaluation.
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